findmyKOL
Clinical trialNCT00300716CompletedPhase 2/PHASE3Interventional

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

SponsorOregon Health and Science UniversityEnrollment82Cognition DisordersMultiple Sclerosis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Usc

    Los Angeles, California, United States

  • Ohsu

    Portland, Oregon, United States

  • Ut Southwestern

    Dallas, Texas, United States

  • Ms Hub

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2004
Primary completion
31 Jan 2009
Completion
31 Jan 2009
Last update posted
15 Oct 2019
Registered enrollment
82
Registry id
NCT00300716

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.